Journal articleAuthors : Orsburn, Benjamin C. (2023)
Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall
prognosis for patients. A recently developed compound, MRTX1133 has shown promise in inhibiting the
KRASG12D mutant protein, which is a primary driver mutation in pancreatic cancer cases worldwide. In this
study, I performed a multi-omic analysis of four cancer cell lines following acute treatment with this
compound. To obtain increased...